Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday, March 17th.
A number of other brokerages have also recently issued reports on ALXN. Leerink Swann restated a “buy” rating and set a $169.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, December 6th. Credit Suisse Group restated a “buy” rating and set a $166.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, December 12th. Robert W. Baird upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price objective for the company in a report on Monday, December 18th. UBS cut Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a report on Thursday, January 4th. Finally, Raymond James Financial restated an “outperform” rating and set a $130.00 price objective (down previously from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals has an average rating of “Buy” and a consensus target price of $155.55.
Shares of NASDAQ ALXN traded down $0.07 during mid-day trading on Friday, hitting $109.24. The company had a trading volume of 2,398,695 shares, compared to its average volume of 2,530,641. The stock has a market capitalization of $24,290.39, a price-to-earnings ratio of 21.17, a PEG ratio of 1.01 and a beta of 1.13. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter last year, the company posted $1.26 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 9.5% on a year-over-year basis. sell-side analysts expect that Alexion Pharmaceuticals will post 6.12 EPS for the current year.
In related news, SVP Heidi L. Wagner sold 1,774 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $206,333.94. Following the sale, the senior vice president now owns 47,212 shares of the company’s stock, valued at $5,491,227.72. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $117.26, for a total transaction of $76,805.30. Following the completion of the sale, the senior vice president now directly owns 32,635 shares in the company, valued at approximately $3,826,780.10. The disclosure for this sale can be found here. Insiders have sold 28,700 shares of company stock valued at $3,345,708 over the last quarter. Company insiders own 4.35% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Delpha Capital Management LLC bought a new stake in shares of Alexion Pharmaceuticals in the fourth quarter worth $102,000. Valeo Financial Advisors LLC bought a new stake in Alexion Pharmaceuticals during the third quarter valued at $147,000. CNB Bank bought a new stake in Alexion Pharmaceuticals during the fourth quarter valued at $150,000. Beacon Investment Advisory Services Inc. bought a new stake in Alexion Pharmaceuticals during the third quarter valued at $201,000. Finally, Invictus RG bought a new stake in Alexion Pharmaceuticals during the third quarter valued at $202,000. 95.36% of the stock is currently owned by institutional investors.
WARNING: “BidaskClub Upgrades Alexion Pharmaceuticals (ALXN) to Sell” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/alexion-pharmaceuticals-alxn-upgraded-at-bidaskclub.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.